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Background: The identification of early-stage colorectal cancer (CRC) with high risk of 
progression is one major clinical challenge, mainly due to lack of validated biomarkers. The 
aims of the present study were to analyze the prognostic impact of three molecular markers 
belonging to the ion channels and transporters family: the ether-à-go-go-related gene 1 
(hERG1) and the calcium-activated KCa3.1 potassium channels, as well as the glucose trans-
porter 1 (Glut-1); and to define the impact of adjuvant chemotherapy in conjunction with the 
abovementioned biomarkers, in a cohort of radically resected stage I–III CRC patients.
Patients and methods: The expressions of hERG1, KCa3.1, and Glut-1 were tested by 
immunohistochemistry on 162 surgical samples of nonmetastatic, stage I–III CRC patients. 
The median follow-up was 32 months. The association between biological markers, clinico-
pathological features, and survival outcomes was investigated by evaluating both disease-free 
survival and overall survival.
Results: Although no prognostic valence emerged for KCa3.1, evidence of a negative impact 
of hERG1 expression on survival outcomes was provided. On the contrary, Glut-1 expression 
had a positive impact. According to the results of the multivariate analysis, patients were strati-
fied in four risk groups, based on TNM stage and hERG1/Glut-1 expression. After adjusting 
for adjuvant therapy, stage I and II, Glut-1-negative, and hERG1-positive patients showed the 
worst survival experience.
Conclusion: This study strongly indicates that the combination of hERG1 positivity and 
Glut-1 negativity behaves as a prognostic biomarker in radically resected CRC patients. This 
combination identifies a group of stage I and II CRC patients with a bad prognosis, even worse 
than that of stage III patients, regardless of adjuvant therapy accomplishment.
Keywords: potassium channels, glucose transporter, biomolecular markers, ion channels, 
prognostic markers
Introduction
Colorectal cancer (CRC) is the world’s third most common cancer in men and the second 
most common in women.1 Primary treatment for patients without distant metastasis is 
surgery. Patients with early-stage CRC could expect a long survival with surgery alone, 
nevertheless ~50% of stage III and 25% of stage II will relapse.2 Adjuvant chemotherapy 
is the standard of care for patients with stage III, while the real benefit in stage II is not still 
clear and the routine use of chemotherapy is not recommended.3 As no validated biomarker 
is available for routinely assessing patients’ risk stratification, the decision on whether to 
accomplish chemotherapy or not for stage II CRC patients currently relies on clinical fea-
tures as T4, number of lymph nodes analyzed, perforation or obstruction, and grading.4
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Therefore, the identification and validation of novel 
biomolecular markers, that could support classical clinico-
pathological parameters in prognostic definition, is one of 
the upmost challenges in the management of CRC. Such 
validated biomarkers would in turn help clinicians to identify 
patients with highest relapse risk and more susceptible to take 
advantage from adjuvant therapy. Until now, microsatellite 
instability (MSI) is an important marker to select patients 
with stage II CRC for adjuvant chemotherapy. Improved sur-
vival from adjuvant therapy has been recently demonstrated 
for patients with proficient DNA mismatch repair (pMMR) 
tumors, whereas patients with high-level microsatellite 
(MSI-H) or defective mismatch repair (dMMR) tumors did 
not show any benefit from fluorouracil (FU)-based therapy.5–8 
For patients with low-grade MSI (85% of all stage II patients), 
a promising way to identify groups that could take advantages 
from adjuvant therapy is ColoPrint (Agendia), an 18-gene 
expression classifier that identifies early-stage colon cancer 
patients at higher risk of disease relapse.9,10 Other similar 
multigene assays, for example, Oncotype DX colon cancer 
assay11 and CoIDx, have been evaluated to support clinicians’ 
decisions, providing prognostic and predictive information. 
Unfortunately, the information obtained from these tests have 
only a prognostic value, and there is no evidence of predic-
tive value about the potential benefit of adjuvant therapy. 
A new frontier in this field is represented by some in-silico 
studies that, making use of large amounts of data originating 
from available independent data sets, can help in identifying 
novel potential biomarkers. The predictive role of the tran-
scription factor CDX2 in stage II CRC was identified with a 
similar approach. Lack of expression of this marker defines a 
group of patients with high relapse risk, which seems to take 
advantage from adjuvant therapy, in terms of survival.12 More 
recently, a microRNA-based model was identified, which 
was capable to enhance in-silico prediction of therapeutic 
response of individual CRC cases.13 Finally, an immune-
derived PD-L1 gene expression profile helped to identify a 
subgroup of stage II and III CRC patients with a favorable 
prognosis that should not receive chemotherapy.14
In this study, the prognostic impact of three potential 
biomarkers belonging to the “ion channels and transporters” 
family was evaluated: two potassium channels (the ether-à-go-
go-related gene 1 [Kv11.1 or hERG1] channel and the “inter-
mediate conductance” calcium-activated KCa3.1 channel, 
encoded by the KCNN4 gene) and the glucose transporter 1 
(Glut-1). hERG1 is a voltage-activated potassium channel 
belonging to the ether à-go-go (EAG) family, frequently 
overexpressed in several types of human cancers15–18 including 
CRC.19–22 KCa3.1 has been shown to be expressed at high 
levels in many human cancers.23–26 Moreover, the impact of 
KCa3.1 on cancer cell proliferation, migration, and invasive-
ness is well described,25–28 and the use of Kca3.1 blockers has 
recently shown promising antitumor effects.29 Recently, the 
expression of KCa3.1 has also been described in CRC,30 but 
its impact as prognostic or predictive value in CRC patients 
is still unknown. Glut-1 is a carrier protein being part of the 
hypoxia pathway, which comprises different biomolecular 
markers (VEGF-A, CA-IX, and EGFR) switched on when 
the oxygen levels in tumor tissues decrease.31–33 Moreover, its 
impact in stage I–III CRC patients has been recently inves-
tigated and correlated to hERG1 expression.34
The aim of the present study was to analyze the prog-
nostic valence of the above three biomarkers in a cohort of 
nonmetastatic, TNM stage I–III CRC patients, considering 
the effects of adjuvant therapy on survival. All the markers 
were tested by immunohistochemistry (IHC) on surgical 
samples, and the most relevant clinicopathological features 
were also included in the study.
Patients and methods
Patients and sample collection
For this study, we enrolled a cohort of 162 patients with 
pathologically confirmed stages I, II, or III colorectal adeno-
carcinoma and treated with radical surgery at the Depart-
ment of General Surgery and Surgical Oncology, Azienda 
Ospedaliero-Universitaria, Careggi, Florence. Patients’ 
cohort was selected without any bias among a group of 
patients treated surgically at the department from September 
2001 to February 2015, excluding patients with chronic hepa-
titis C viral infection and those with rectal cancer who had 
received neoadjuvant radiotherapy or chemotherapy before 
surgery. After obtaining an informed written consent from 
each patient, samples of tumor were collected during surgery 
and treated for IHC analysis, as described later. The study was 
carried out with approval of the ethics committee of Azienda 
Ospedaliero-Universitaria Careggi. The classification of 
adenocarcinomas was conducted under optical microscope, 
and tumors were staged according to the American Joint 
Committee on Cancer classification. All patients with disease 
relapse were treated according to the local guidelines. More-
over, a subgroup of 92 patients (56.8%) with stage II and III 
CRC received adjuvant chemotherapy after surgery.
ihc
For patients enrolled in the study, formalin-fixed, paraffin- 
embedded, 7-µm sections were stained by using a commercially 
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available kit (PicTure Plus kit and DAB; Zymed, Carlsbad, 
CA, USA), as described previously.34 Briefly, the antigen 
retrieval for hERG1 and Glut-1 staining was performed by 
treatment with proteinase K (5 µg/mL), whereas for KCa3.1 
staining the samples are heated in a microwave oven at 
600 W in citrate buffer pH 6.0 for 15 minutes. Stainings 
were performed by using antibodies to hERG1 (1:200; mono-
clonal antibody produced in our laboratory and distributed 
by Dival Toscana Srl), KCa3.1 (1:2,000, polyclonal rabbit 
anti-human KCNN4; Sigma-Aldrich, St Louis, MO, USA), 
and Glut-1 (1:100, polyclonal rabbit anti-human GLUT1; 
DakoCytomation, Glostrup, Denmark). Tissue slides were 
analyzed at a total magnification of 40× field by field, from 
top left to bottom right, and classified with a scoring system 
different for each marker. For hERG1, the scoring method 
described by Lastraioli et al34 was followed: specimens were 
classified as “score 0” where no staining was present, speci-
mens with a percentage of neoplastic-stained cells ranging 
from 1% to 49% were classified as “score 1,” and specimens 
with a percentage of stained cells .50% were classified as 
“score 2.” For the purpose of the analysis, only samples 
classified with “score 2” (with a high hERG1 expression) 
were considered “hERG1-positive.” For KCa3.1 and Glut-1, 
only specimens where at least 1% of marked cells were pres-
ent, without applying any scoring system, were considered 
positive.30,34,35 Each specimen was analyzed by two inde-
pendent investigators, and the interobserver agreement was 
evaluated according to the simple Cohen κ of concordance 
and its 95% confidence interval (CI). Images were acquired 
on a Leica DM 4000B microscope with a Leica DFC 320 
Camera using Leica QWin software (Leica Microsystems, 
Milan, Italy).
statistical methods
For each patient, the following clinicopathological variables 
were investigated: age at the intervention, sex, site of tumor, 
TNM classification, tumor histological grading, mucin 
content, and adjuvant therapy. Moreover, for each tumor 
tissue, the expressions of hERG1, KCa3.1, and Glut-1 were 
also assessed, and each marker was categorized as yes/no 
with respect to their expression. The association between 
clinicopathological features and biological markers was 
evaluated by χ2 and Fisher’s exact tests when appropriate. A 
two-sided P#0.05 was considered significant. The impact of 
each parameter on survival was analyzed by evaluating two 
variables: disease-free survival (DFS), defined as the time 
from intervention to death or recurrence of disease, whatever 
the cause, and overall survival (OS). The Kaplan–Meier 
inverse method was applied to establish the median follow-up 
time.36 The statistical analysis was performed as described 
previously.34 Briefly, DFS and OS were calculated according 
to the Kaplan–Meier product-limit method,37 first at the uni-
variate analysis, and the Cox proportional hazard model was 
used to calculate the hazard ratios (HRs) and appropriate 95% 
CIs. Subsequently, the independent effect of each parameter 
on both the survival variables was investigated by a multivari-
ate Cox regression model. As in Lastraioli et al,34 starting 
from a model including all the clinicopathological variables 
and the biological markers, nonsignificant variables were 
progressively removed, according to a backward stepwise 
procedure based on the likelihood ratio test. Finally, for each 
risk group of patients identified, a Cox proportional hazards 
model (with the average covariate method) was applied to 
obtain the nonparametric evaluation of the survivor functions 
and accompanying HRs, adjusted for adjuvant treatment. 
Data were analyzed using the statistical software SAS 9.2 
(SAS Corporation, Cary, NC, USA).
Results
characteristics of the patients’ cohort
Primary tumor samples were collected from 162 patients 
diagnosed as stage I–III CRC. The clinicopathological 
features of the patients’ cohort are summarized in Table 1. 
Among 162 patients, 86 (53.1%) were female and 76 (46.9%) 
were male. Patients’ age ranged from 40 to 90 years, with 
a median age of 69 years. Ninety-two patients (56.8%) 
received adjuvant chemotherapy after surgery. Tumors 
were mostly located in the right colon (73), whereas 39 
were located in the left, 14 in the transverse colon, and 36 
in the rectum.
analysis of herg1, Kca3.1, and glut-1 
expressions
In all the samples, the expressions of hERG1 and KCa3.1 
potassium channels, as well as that of the glucose transporter 
Glut-1, by IHC, were investigated using different scoring 
systems for the three markers (see “Materials and methods”). 
Figure 1 shows IHC representative pictures relative to 
samples with different scorings of hERG1 (Figure 1A–C), 
KCa3.1 (Figure 1D and E), and Glut-1 (Figure 1F and G).
hERG1 turned out to be expressed (ie, score 2) in 40 
out of 162 CRC primary tissues (24.7%), KCa3.1 in 56.8% 
(92/162), and Glut-1 in 34.6% (56/162) of samples (Table 1). 
The expressions of hERG1 and Glut-1 were significantly 
associated (P=0.001), whereas no significant association 
between KCa3.1 and the other two biomarkers emerged.
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association analysis
The associations between the expressions of the three biomo-
lecular markers and the clinicopathological characteristics 
of the patients were analyzed. No significant association 
emerged between the expressions of the two potassium 
channels and clinicopathological characteristics such as age, 
TNM stages, sex, histological grading, and adjuvant therapy. 
KCa3.1 was mainly expressed in mucinous CRC primary 
samples (71.4% mucinous tumors vs 52.5% nonmucinous 
tumors; P=0.045), and an association, although not sig-
nificant, was found between hERG1 and tumor site, with 
the channel more expressed in transverse and left colon 
(P=0.267).
Glut-1 expressed more in patients aged ,70 years (42.4% 
vs 26%; P=0.029) and in left and transverse colon (27.4%, 
42.9%, 53.9%, and 25% for right colon, transverse colon, left 
colon, and rectum, respectively; P=0.019). Glut-1 was less 
frequently detected in mucinous tumors (P=0.088).
impact on survival outcomes
The impact on survival was analyzed evaluating both DFS and 
OS. Patients were followed up for a median time of 32 months. 
Thirty of 162 patients (18.5%) had a disease relapse and 
32 (19.8%) died during follow-up. The univariate analysis 
(Table 1) showed that TNM stage, adjuvant therapy, and Glut-1 
expression have a significant impact on DFS and OS: TNM 
stage III and adjuvant therapy emerged as indicators of worse 
prognosis, whereas Glut-1 had a positive impact on survival.
The multivariate analysis (Table 2) confirmed the trends 
of stage III TNM, adjuvant therapy, and Glut-1 expression 
and also showed a significant negative impact of hERG1 
expression on both DFS and OS. For KCa3.1, both univariate 
Table 1 Univariate analysis of clinicopathological and biomolecular markers for DFs and Os
Parameter Patients, n (%) DFS OS
3-year DFS HR (95% CI) P-value 3-year OS HR (95% CI) P-value
age 0.98 0.44
,70 years 85 (52.5%) 61.7% 1 (ref) 65.2% 1 (ref)
.70 years 77 (47.5%) 55.6% 0.99 (0.60–1.63) 59.6% 1.23 (0.72–2.14)
sex 0.88 0.59
Female 86 (53.1%) 57.2% 1 (ref) 62.1% 1 (ref)
Male 76 (46.9%) 59.7% 1.04 (0.62–1.71) 62.5% 1.16 (0.67–2.00)
Tumor site 0.94 0.43
right colon 73 (45.1%) 57.8% 1 (ref) 55.7% 1 (ref)
Transverse colon 14 (8.6%) 51.6% 0.83 (0.34–2.06) 51.6% 0.96 (0.39–2.37)
left colon 39 (24.1%) 74.1% 0.83 (0.44–1.58) 80.5% 0.56 (0.26–1.19)
rectum 36 (22.2%) 49.5% 0.89 (0.47–1.68) 60.5% 0.63 (0.36–1.45)
TnM stage 0.01 0.04
stage i 32 (19.7%) 70.6% 1 (ref) 73.0% 1 (ref)
stage ii 57 (35.2%) 67.9% 0.98 (0.42–2.30) 77.0% 0.88 (0.35–2.21)
stage iii 73 (45.1%) 46.8% 2.08 (0.97–4.47) 47.8% 1.84 (0.81–4.18)
Mucin 0.69 0.75
no 120 (74.1%) 57.4% 1 (ref) 63.3% 1 (ref)
Yes 42 (25.9%) 60.6% 0.89 (0.51–1.56) 59.7% 1.10 (0.61–2.00)
histological grading 0.47 0.79
g1 16 (9.9%) 57.7% 1 (ref) 57.1% 1 (ref)
g2–g3 146 (90.1%) 58.6% 0.69 (0.25–1.91) 62.9% 0.87 (0.31–2.43)
adjuvant 0.01 0.01
no 70 (43.2%) 76.0% 1 (ref) 76.4% 1 (ref)
Yes 92 (56.8%) 45.4% 2.78 (1.58–4.88) 51.6% 2.34 (1.28–4.28)
herg1 0.26 0.17
negative 122 (75.3%) 60.4% 1 (ref) 64.5% 1 (ref)
Positive 40 (24.7%) 51.2% 1.38 (0.78–2.46) 54.0% 1.54 (0.83–2.85)
Kca3.1 0.55 0.86
negative 70 (43.2%) 57.8% 1 (ref) 58.0% 1 (ref)
Positive 92 (56.8%) 59.3% 0.86 (0.51–1.42) 64.9% 1.05 (0.60–1.84)
glut-1 0.02 0.01
negative 106 (65.4%) 49.5% 1 (ref) 54.9% 1 (ref)
Positive 56 (34.6%) 78.0% 0.51 (0.28–0.91) 78.2% 0.410 (0.21–0.80)
Note: Statistically significant parameters are highlighted in bold.
Abbreviations: CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; OS, overall survival.
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and multivariate analyses did not show any statistically 
relevant association with the survival outcomes. For risk 
stratification analysis, all the variables that did not show any 
significant independent effect on DFS and OS were progres-
sively removed. After adjusting for adjuvant treatment, this 
analysis led to stratification of the patients into four different 
risk groups, based on TNM stages and hERG1/Glut-1 expres-
sion. Three groups encompass TNM stage I and II patients, 
who are further subdivided on the basis of the expression of 
hERG1 and Glut-1, and the fourth group comprises stage III 
patients independently on the molecular phenotype. As 
shown in Figure 2 and Table 3, the group comprising Glut-
1-negative and hERG1-positive stage I and II patients had 
the worst survival experience.
Discussion
The present study was aimed at identifying novel biomolecu-
lar markers to be employed in the clinical practice for the 
identification of high-risk early-stage CRC patients, for fur-
ther selection of treatment options. The prognostic impact of 
two potassium channels hERG1 and KCa3.1, as well as that 
of Glut-1, in a cohort of 162 surgically resected, stages I–III 
CRC patients was analyzed. It is evident that, independent 
of adjuvant treatment effect, 1) three main variables signifi-
cantly impact on survival (both OS and DFS): TNM (negative 
when stage III), hERG1 (negative), and Glut-1 (positive); 2) 
hERG1 positivity and Glut-1 negativity serve to identify a 
subset of stage I and II CRC patients whose survival curves 
are worse than those of stage III CRC patients.
Figure 1 immunohistochemical scoring for all markers in crc primary samples.
Notes: (A–C) representative examples of herg1 scoring in crc specimens using the anti-herg1 monoclonal antibody: (A) score 0 (0% of positive cells), (B) score 1 
(1%–49% of positive cells per microscopic field), and (C) score 2 (.50% of positive cells per microscopic field). Note that only samples belonging to score 2 were considered 
positive. (D and E) representative example of Kca3.1 scoring: negative (D) and positive (E) representative crc specimens. (F and G) glut-1 scoring in representative crc 
specimens: (F) negative and (G) positive samples. Original magnification: 200×. scale bars: 50 µm.
Abbreviations: CRC, colorectal cancer; IHC, immunohistochemistry.
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Nowadays, the identification of novel prognostic bio-
markers is mandatory, in order to help clinicians in risk 
stratification and decision making in the treatment of CRC 
patients with early-stage, in particular stage II, disease.38 
Indeed, it is well known that a subgroup of stage II patients, 
usually not treated with adjuvant chemotherapy, recurs after 
surgery.39 Those stage II patients whose disease recurs would 
benefit from adjuvant chemotherapy, like those with a TNM 
stage III disease. Hence, clinicians continue to grapple with 
the problem of determining those stage II patients most 
likely to derive benefits from adjuvant chemotherapy, in order 
to improve the outcomes in this patient population and, in 
the meantime, avoid potentially toxic overtreatments. The 
most important parameters among a handful of prognostic 
variables that are considered for treatment choices are only 
tumor stage, tumor grade, and MSI.40,41
In the present study, the expression and the prognostic 
impact of two potassium channels, hERG1 and KCa3.1, 
whose aberrant expression has been strongly associated to 
many human cancer, including CRC, were investigated.15–30 
The expression of Glut-1, another cancer biomarker, belong-
ing to the hypoxia signaling pathway was also investi-
gated.31–33 Moreover, a previous observation, obtained in 
a pilot study, demonstrated a significant association and 
prognostic valence for the combined hERG1 and Glut-1 
expressions in CRC patients.34
The expression of KCa3.1 channel was detected in .50% 
of CRC primary samples. Unexpectedly, our data did not 
show any diagnostic or prognostic relevance for KCa3.1 
expression, at least in nonmetastatic CRC, even though 
its role in driving tumor progression and its association 
to poor prognosis in other types of human cancer are well 
recognized.23–30
On the contrary, hERG1 expression displayed a negative 
impact on survival outcomes that, although nonsignificant 
at the univariate analysis, reached significance in the multi-
variate model. Most parameters losing their valence, when 
Table 2 Multivariate analysis of factors related to DFs and Os 
(by the cox’s regression model)
Parameter DFS OS
HR (95% CI) P-value HR (95% CI) P-value
TnM stage 0.0110 0.0060
i 1 (ref) 1 (ref)
ii 0.43 (0.17–1.10) 0.39 (0.14–1.08)
iii 1.16 (0.48–2.79) 1.16 (0.46–2.92)
herg1 0.0127 0.0058
negative 1 (ref) 1 (ref)
Positive 2.57 (1.40–4.73) 2.75 (1.43–5.29)
Kca3.1 0.0708 0.3109
negative 1 (ref) 1 (ref)
Positive 0.59 (0.34–1.04) 0.72 (0.38–1.35)
glut-1 0.0004 ,0.0001
negative 1 (ref) 1 (ref)
Positive 0.32 (0.17–0.60) 0.24 (0.12–0.49)
adjuvant 0.0001 0.0012
no 1 (ref) 1 (ref)
Yes 3.42 (1.75–6.67) 3.03 (1.50–6.13)
Abbreviations: CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; 
Os, overall survival.
Figure 2 Kaplan–Meier curves of overall and disease-free survival according to different combinations of tumor characteristics (TnM stage, glut-1, and herg1 status).
Notes: Kaplan–Meier plots of (A) overall survival (Os) and (B) disease-free survival (DFs) probabilities for four different groups are reported. Blue curve indicates stage i 
and II Glut-1-positive samples (27 patients, 16.7%); red curve, stage I and II Glut-1-negative and hERG1-positive samples (eleven patients, 6.8%); green curve, stage I and II 
Glut-1-negative and hERG1-negative samples (51 patients, 31.5%); brown curve, stage III samples (73 patients, 45.1%).
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analyzed under the multivariate models, is an unusual feature. 
However, the negative impact of hERG1 on prognosis is not 
surprising, as the impact of hERG1 on tumor progression has 
been proven by several published papers.15–22
Glut-1 showed the strongest correlation with clinico-
pathological features. In fact, statistically relevant correla-
tions emerged with age (more expressed in ,70 years cluster) 
and tumor site (more expressed in left colon and transverse). 
Furthermore, Glut-1 positively impacted on the survival at 
both the univariate and multivariate analyses. Such a posi-
tive impact is apparently in contrast with the common view 
considering Glut-1, being a hypoxia marker, as a tumor 
progression factor.31–33,42,43 As discussed in Lastraioli et al,34 
it is believed that the highest Glut-1 expression occurs at a 
preangiogenic phase of tumor progression, and its disappear-
ance marks the onset of angiogenesis, the true progression 
step underlying the acquisition of full malignancy in CRC.
Overall, four variables expressed a significant impact 
on survival: TNM stages, therapy, hERG1, and Glut-1 
expressions. The negative impact on the survival of TNM 
is well defined.44 The negative prognostic role of adjuvant 
therapy may appear contradictory, as it was developed with 
the purpose of improving survival. Until now, this negative 
impact has been misleading, because it depends more on 
the clinical characteristics of the group of patients (either 
stage III or II) who were selected for treatment than on the 
effects of treatments.
The most novel and relevant result emerging from the 
present study was that a strong hERG1 expression, combined 
with the lack of Glut-1 expression, is associated with signifi-
cant worsening of the prognosis of surgically resectable early 
stages of CRC patients. The present risk analysis, besides 
confirming a previous pilot study,34 led to an even stronger 
evidence that the outcome of hERG1-positive/Glut-1-negative 
patients is worse than that of stage III patients.
On the whole, based on the results reported here, it has been 
proposed that an IHC-based test addressing hERG1 and Glut-1 
detection (hERG1/Glut-1 test) could be used in stage II CRC 
Table 3 association between risk groups and survival outcomes adjusted for adjuvant treatment (by means of cox’s proportional 
hazard model)
Parameter Patients (n) DFS OS
3-year DFS HR (95% CI) P-value 3-year OS HR (95% CI) P-value
TnM iii 73 52.9% 1 (ref) 0.032 56.2% 1 (ref) 0.021
TnM i/ii glut-1+ 27 86.8% 0.22 (0.05–0.95) 85.9% 0.26 (0.06–1.14)
TnM i/ii glut-1- herg1+ 11 40.8% 1.41 (0.58–3.40) 33.7% 1.89 (0.77–4.70)
TnM i/ii glut-1- herg1- 51 66.6% 0.64 (0.35–1.17) 72.6% 0.56 (0.28–1.11)
Abbreviations: CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; OS, overall survival.
patients to determine the individual risk of cancer recurrence. 
Alone, or in conjunction with MSI or CDX2 analysis, the 
hERG1/Glut-1 test could accompany, or even substitute, more 
complex biomolecular tests. Furthermore, it has been proposed 
to accomplish an appropriately designed study to confirm the 
predictive potential of hERG1 positivity and Glut-1 negativ-
ity. Once validated in a clinical study, the hERG1/Glut-1 test 
would contribute to identify those stage II patients with likeli-
hood of benefit from adjuvant chemotherapy.
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